Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma

Carcinoma, Hepatocellular Clinical Trial

Official title: Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma

Status Terminated

Clinical Trial Summary

The objective of this study is to study the safety and tumor response of ACE for large HCC.

Clinical Trial Description

Transarterial treatment has been playing an important role in the treatment algorithm for patients with multifocal or large intrahepatic hepatocellular carcinoma not eligible for surgical resection, transplantation, or local ablative therapy. Among the patient group with intermediate tumor stage, in which the tumor dimension exceeds 10cm, the treatment outcome of conventional chemoembolization (cTACE), chemoembolization using drug eluting beads (DEB-TACE) and radioembolization using yttrium 90 is generally unsatisfactory. Some would consider HCC of size >10cm a relative contraindication for cTACE because of the poor treatment outcome. However, there is no better alternative treatment for local control of these tumors. Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin has been found to be highly effective for local control of HCC as compared to cTACE in a case-control study. It is hypothesized that ACE is safe and effective for local control of large HCC of size >10cm. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

• NCT number: NCT03662841
• Study type: Interventional
• Source: Chinese University of Hong Kong
• Status: Terminated
• Phase: N/A
• Start date: July 13, 2018
• Completion date: April 28, 2023